WallStreetZenWallStreetZen

NASDAQ: KALA
Kala Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their KALA stock forecasts and price targets.

Forecast return on equity

Is KALA forecast to generate an efficient return?

Company
N/A
Industry
49.7%
Market
175.99%

Forecast return on assets

Is KALA forecast to generate an efficient return on assets?

Company
N/A
Industry
18.93%

KALA earnings per share forecast

What is KALA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.26
Avg 2 year Forecast
-$0.41

KALA revenue forecast

What is KALA's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

KALA vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
KALA$3.61N/AN/A
CTOR$0.67N/AN/A
TLPH$1.09$3.00+175.23%Strong Buy
INCR$0.93N/AN/A
CPIX$5.72N/AN/A
View Top Pharmaceutical Stocks

Kala Bio Stock Forecast FAQ

What is KALA's earnings growth forecast for 2026-2027?

(NASDAQ: KALA) Kala Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 13.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.

Kala Bio's earnings in 2026 is -$19,654,000.On average, 3 Wall Street analysts forecast KALA's earnings for 2026 to be -$23,512,420, with the lowest KALA earnings forecast at -$22,590,364, and the highest KALA earnings forecast at -$24,203,961.

In 2027, KALA is forecast to generate -$7,584,651 in earnings, with the lowest earnings forecast at -$7,287,214 and the highest earnings forecast at -$7,807,729.

If you're new to stock investing, here's how to buy Kala Bio stock.

What is KALA's revenue growth forecast for 2026-2028?

(NASDAQ: KALA) Kala Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Kala Bio's revenue in 2026 is $0.On average, 3 Wall Street analysts forecast KALA's revenue for 2026 to be $0, with the lowest KALA revenue forecast at $0, and the highest KALA revenue forecast at $0. On average, 3 Wall Street analysts forecast KALA's revenue for 2027 to be $0, with the lowest KALA revenue forecast at $0, and the highest KALA revenue forecast at $0.

In 2028, KALA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KALA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: KALA) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 18.93%.

What is KALA's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: KALA) Kala Bio's current Earnings Per Share (EPS) is -$98.14. On average, analysts forecast that KALA's EPS will be -$1.26 for 2026, with the lowest EPS forecast at -$1.22, and the highest EPS forecast at -$1.30. In 2027, KALA's EPS is forecast to hit -$0.41 (min: -$0.39, max: -$0.42).

What is KALA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: KALA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.